Helium has been the preferred carrier gas for gas chromatography (GC) testing, but its finite supply, environmental impact, and recent supply chain issues have prompted Eurofins Lancaster BioPharmaceutical Chemistry teams to actively seek alternatives and reduce helium usage in laboratories. Conservation efforts include evaluating gas chromatography methods, checking for helium leaks during audits, and avoiding idle periods between analytical runs. Nitrogen and hydrogen are explored as alternatives, with challenges noted. Eurofins is committed to developing strategies to conserve or eliminate helium usage, recognizing the importance of reducing reliance on this non-renewable resource in the industry.
Flexible-Dose Development Strategies for Today's Clinical Landscape - Executive Summary
January 8th 2025This executive summary focuses on dose-flexible manufacturing strategies and their role in drug development. Dose flexibility is increasingly important for early clinical studies, particularly in areas such as pediatric medicines and oncology. However, flexible dosing strategies are often neglected or not prioritized early in development. This presentation will focus on technical strategies that can help anticipate appropriate timing for implementation and how to do so cost effectively while adhering to required timelines.
Molecular Properties of PROTACs and the Relationship to Formulation Design
December 20th 2024Analyzation of a diverse set of PROTAC (Proteolysis Targeting Chimeras – a class of TPDs) structures and their calculated properties, identifying key structure-property trends that contribute to low oral bioavailability.
Clinical Supply Planning in Europe - Balancing Cost, Flexibility and Time
December 19th 2024The packaging and distribution of clinical supplies is a fundamental piece to the overall success of a clinical trial, and advance preparation can help establish a more efficient supply chain. Selecting the best geographical location for those activities, however, depends on the clinical trial protocol, business decisions, and even the investigational medicinal product (IMP) being studied.